SYNDAX PHARMACEUTICALS INC (SNDX)

Company Profile

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the development of cancer therapies. The company is headquartered in Waltham, Massachusetts and currently employs 112 full-time employees. The company went IPO on 2016-03-03. The company is focused on developing pipeline of cancer therapies. Its product candidates include revumenib, and axatilimab. The company is developing revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant A. The company is also exploring the use of revumenib as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. The company is also developing axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.

Company Info

SYNDAX PHARMACEUTICALS INC

35 Gatehouse Drive, Building D, Floor 3

Waltham MASSACHUSETTS 02451

P: 17814191400

CEO: Briggs W. Morrison

Employees: 112

Website: https://syndax.com/